Rilzabrutinib治疗抗组胺药难治性慢性自发性荨麻疹:RILECSU 2期随机临床试验
RILECSU 2期试验纳入160例抗组胺药控制不佳的中重度慢性自发性荨麻疹患者,评估口服BTK抑制剂rilzabrutinib的疗效与安全性。主要分析集为143例未使用过奥马珠单抗者,1200 mg/d组第12周ISS7和UAS7较安慰剂显著改善,且起效快、安全性可接受。
要点
- rilzabrutinib 1200 mg/d可显著降低第12周ISS7和UAS7,差异分别为-3.44和-6.75。
- ISS7、UAS7、HSS7和AAS7改善最早见于第1周。
- 常见不良事件为腹泻、恶心和头痛,风险获益比良好。
核心结论
- rilzabrutinib 1200 mg/d治疗12周对H1抗组胺药难治的中重度CSU有效且起效快,不良事件可接受。
研究设计与样本
- RILECSU为52周2期随机临床试验,含12周双盲安慰剂对照剂量递增期和40周开放标签延长期。
- 51个中心在亚洲、欧洲、北美和南美12个国家入组18至80岁中重度CSU成人患者。
- 患者按1:1:1:1随机接受rilzabrutinib 400 mg/d、800 mg/d、1200 mg/d或安慰剂。
- 共160例患者随机,平均年龄44.1岁,女性112例(70.0%);主要分析集为143例未使用过奥马珠单抗者。
主要发现
- HSS7和AAS7亦观察到改善,且ISS7、UAS7、HSS7和AAS7改善最早见于第1周。
- 第12周CSU相关生物标志物较安慰剂降低,包括sMRGPRX2、IgG抗TPO、IgG抗FcεRI和IL-31。
- rilzabrutinib较安慰剂更常见的不良事件包括腹泻、恶心和头痛。
关键数值与推荐
- 主要终点为第12周ISS7(美国及美国参考国家)或UAS7(非美国参考国家)较基线变化。
- 入组标准为UAS7≥16且ISS7≥8,且H1抗组胺药治疗控制不佳。
临床怎么用
- 对于H1抗组胺药难治的中重度CSU患者,rilzabrutinib 1200 mg/d可作为候选治疗。
- 治疗早期即可评估疗效,关注腹泻、恶心和头痛等不良事件。
局限性
- 主要分析仅纳入未使用过奥马珠单抗患者,长期疗效和潜在危害需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chronic spontaneous urticaria (CSU) is a skin disease driven mainly by the activation of cutaneous mast cells through various mechanisms. Bruton tyrosine kinase (BTK), expressed in B cells and mast cells, plays a critical role in multiple immune-mediated disease processes. OBJECTIVE: To determine the efficacy and risk profile of rilzabrutinib (SAR444671), an oral, reversible, covalent, next-generation BTK inhibitor, in treating patients with CSU. DESIGN, SETTING, AND PARTICIPANTS: The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension. The trial was conducted from November 24, 2021, through April 23, 2024. Fifty-one centers enrolled and randomized participants across 12 countries in Asia, Europe, North America, and South America. The trial participants included adults aged 18 to 80 years with moderate to severe CSU (weekly Urticaria Activity Score [UAS7] of 16 or more; weekly Itch Severity Score [ISS7] of 8 or more) not adequately controlled with H1-antihistamine treatment. INTERVENTIONS: Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo. MAIN OUTCOMES: The primary end point was change from baseline at week 12 in ISS7 (for US and US reference countries) or UAS7 (for non-US reference countries). RESULTS: A total of 160 omalizumab-naive and omalizumab-incomplete responders were randomized (mean [SD] age, 44.1 [13.4] years; 112 [70.0%] female). The primary analysis population included only the 143 omalizumab-naive patients. Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, -9.21 vs -5.77; difference, -3.44 [95% CI, -6.25 to -0.62]; P = .02) and UAS7 (LS mean, -16.89 vs -10.14; difference, -6.75 [95% CI, -12.23 to -1.26]; P = .02). In addition, improvements in weekly Hives Severity Score (HSS7) and weekly Angioedema Activity Score (AAS7) were observed. Improvements in ISS7, UAS7, HSS7, and AAS7 were observed as early as week 1. CSU-related biomarkers, including soluble Mas-related G protein-coupled receptor X2, immunoglobulin (Ig)-G antithyroid peroxidase, IgG anti-Fc-ε receptor 1, and interleukin-31, were reduced compared to placebo at week 12. Rilzabrutinib demonstrated a favorable risk-benefit profile; adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache. CONCLUSIONS AND RELEVANCE: The results of the RILECSU randomized clinical trial demonstrated efficacy and rapid onset of action of rilzabrutinib, 1200 mg/d, over 12 weeks, in addition to an acceptable adverse event profile. Together, these data support the use of rilzabrutinib in treating patients with moderate to severe CSU refractory to H1-antihistamines. Further research is needed to determine long-term efficacy and potential harms. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05107115.
引用
- Giménez-Arnau A, Ferrucci S, Ben-Shoshan M, et al. Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 40266575. doi:10.1001/jamadermatol.2025.0733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。